Epigenetics Drug-discovery: From Target to Patients with BET Bromodomain Inhibitors
Rabinder Prinjha,
VP, Head of Epinova Epigenetics,
GlaxoSmithKline
Dramatic progress in the understanding and druggability of epigenetic targets has enabled the transition of many agents from preclinical evaluation to studies in patients. I will discuss the scientific framework that’s informing our excitement about epigenetics and advances in understanding of the bromodomain containing family of proteins.
|
|
